Author:
Kushlinskii N. E.,Alferov A. A.,Timofeev Yu. S.,Gershtein E. S.,Bulycheva I. V.,Bondarev A. V.,Shchupak M. Yu.,Sokolov N. Yu.,Polikarpova S. B.,Efimova M. M.,Dzampaev A. A.,Sushentsov E. A.,Aliev M. D.,Musaev E. R.
Publisher
Springer Science and Business Media LLC
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference15 articles.
1. Gershtein ES, Utkin DO, Goryacheva IO, Khulamkhanova MM, Petrikova NA, Vinogradov II, Alferov AA, Stilidi IS, Kushlinskii NE. Soluble forms of immune checkpoint receptor PD-1 and its ligand PD-L1 in plasma of patients with ovarian neoplasms. Al’manakh Klin. Med. 2018;46(7):690-698. Russian.
2. Ding Y, Sun C, Li J, Hu L, Li M, Liu J, Pu L, Xiong S. The Prognostic significance of soluble programmed death ligand 1 expression in cancers: a systematic review and meta-analysis. Scand. J. Immunol. 2017;86(5):361-367.
3. Guo X, Wang J, Jin J, Chen H, Zhen Z, Jiang W, Lin T, Huang H, Xia Z, Sun X. High serum level of soluble programmed death ligand 1 is associated with a poor prognosis in Hodgkin lymphoma. Transl. Oncol. 2018;11(3):779-785.
4. Huang HF, Zhu H, Yang XT, Guo XY, Li SS, Xie Q, Tian XB, Yang Z. Progress in research on tumor immune PD-1/PD-L1 signaling pathway in malignant bone tumors. Zhonghua Zhong Liu Za Zhi. 2019;41(6):410-414.
5. Kabir TF, Chauhan A, Anthony L, Hildebrandt GC. Immune Checkpoint Inhibitors in Pediatric Solid Tumors: Status in 2018. Ochsner J. 2018;18(4):370-376.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献